Business Wire

Xilam: H1 2017 Revenue: +67%

Del

Regulatory News:

The Xilam Group (Paris:XIL) posted consolidated H1 2017 revenue of EUR 9.239 million, an increase of 67%. The revenue breakdown is as follows:

In EUR 000   30.06.2017 (1)   30.06.2016   Change
New productions(2)   4,571   4,036   +13.3%
Catalogue   4,652   1,491   +212.0%
Other   16   21   -23.8%
Revenue   9,239   5,548   +66.5%

(1) unaudited data
(2) including subsidies and development

Solid growth

An excellent 1H performance was driven by the two main segments, Catalogue and New Productions.

Catalogue revenue tripled over the period, taking Xilam to the next level of its development. This increase stemmed from significant sales to both TV channels and digital platforms. In particular, sales to digital platforms jumped 149% to account for 40% of Catalogue revenue. Growth on the YouTube platforms is continuing its upward trajectory, with 1.12 billion views.

New Productions also performed well. This segment posted revenue of EUR 4.6 million, an increase of more than 13%, boosted by delivery of the latest episodes of Rolling with the Ronks! and further deliveries from season 5 of Oggy & the Cockroaches .

Strong international growth continues

International sales accounted for more than 67% of H1 revenue, an increase of over 194% during the period, thereby consolidating Xilam’s position as a global leader in the animation market.

Xilam content is now shown in more than 160 countries and in 600 million households.

Xilam has secured a number of major contracts for TV and on the leading digital platforms

On top of a solid revenue performance, the first half also saw the signing of several contracts that will further strengthen Xilam’s growth potential in the coming years:

  • The signing of a global distribution agreement with Amazon for its two flagship series Oggy & the Cockroaches and Zig & Sharko
  • The signing of an agreement with Netflix on three series that are currently in production
  • The signing of a new agreement with the Disney Channel for the broadcast of Oggy & the Cockroaches in Germany

Also in the first half of the year, Xilam signed a master toy licensing agreement with Lansay, which should gradually increase merchandising revenue.

Record full-year 2017 revenue expected

After a successful first half to the year, the pace of programme delivery will increase in the second half, to account for two-thirds of 2017 deliveries. Xilam is confident that it will post record revenue in 2017.

Season 5 of Oggy & the Cockroaches already a success

Global advance sales for the new season of Oggy & the Cockroaches were exceptional, and the first programmes will be launched in the third quarter of 2017, notably on Gulli in France, Discovery in Italy, Disney in Germany and Cartoon Network for the whole of Asia.

The quality of this series, along with the projected global distribution and multi-platform programming, will give the Oggy brand unprecedented exposure.

A step-up in production capacity

The upgraded studios that came on stream in 2016 (in Vietnam, Lyon and Angoulême) are now fully operational, enabling Xilam to confirm its ability to deliver about 350 half hours of programmes in 2017-2020.

New series in development

Production of the Mr Magoo series began in early 2017, and Xilam is currently developing a number of new series, including:

  • Coach me if you can
  • Zig & Sharko 3
  • Rolling with the Ronks! 2
  • Petit Méchant Loup [Little Bad Wolf]
  • The fabulous adventures of prince Moka

Coach me if you can and Zig & Sharko 3 are scheduled to enter production in the second half of 2017.

A stronger, more hands-on management team

To support its expansion, Xilam has strengthened its management structure with the arrival of François Bardoux (CFO), Morgann Favennec (Executive VP Development & Global Sales) and Nicolas Halftermeyer (SVP Marketing and Digital), and the internal promotion of François-Xavier de Maistre (Executive VP Organisation and Human Resources).

About Xilam

Xilam is one of Europe’s leading animation companies, producing and distributing original children’s and family entertainment content in both 2D and 3D formats across TV, film and digital media platforms.

Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and 3 feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons, Rolling with the Ronks! and its first pre-school series, Paprika.

Broadcast in over 160 countries on all the major TV networks, these series are also breaking audience records on all the major digital platforms, including YouTube with over 2.2 billion views in 2016, ranking Xilam as one of the top global content providers in animation.

Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.

Xilam is listed on Euronext Paris / Ticker: XIL / ISIN code: FR0004034072

Xilam is eligible for the PEA-PME investment scheme.

Contact information

Xilam
Marc du Pontavice – Chairman and CEO
François Bardoux – CFO
Tel: (33) 01 40 18 72 00

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha